Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$20.35 -0.1%	$18.91	$14.40 ▼ $47.00	$1.35B	1.39	895,300 shs	477,438 shs
EBS Emergent BioSolutions	$6.40 -1.5%	$5.24	$4.02 ▼ $15.10	$347.38M	2.09	1.85 million shs	1.18 million shs
MNKD MannKind	$4.12 -2.4%	$4.75	$4.05 ▼ $7.63	$1.25B	1.14	2.38 million shs	2.03 million shs
NVAX Novavax	$7.25 -0.5%	$6.62	$5.01 ▼ $23.86	$1.17B	3.21	7.29 million shs	5.57 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-0.10%	-0.49%	+4.73%	-9.39%	-46.59%
EBS Emergent BioSolutions	-1.08%	-3.83%	+28.39%	-17.32%	+27.49%
MNKD MannKind	-2.37%	-5.72%	-10.82%	-28.53%	-14.52%
NVAX Novavax	-0.55%	+7.73%	-3.13%	-9.26%	-53.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	1.9641 of 5 stars	4.5	0.0	0.0	3.7	0.0	0.0
EBS Emergent BioSolutions	4.399 of 5 stars	3.5	3.0	4.6	2.4	2.5	1.3
MNKD MannKind	2.9701 of 5 stars	3.6	1.0	0.0	3.4	1.7	1.9
NVAX Novavax	3.7146 of 5 stars	3.2	1.0	4.7	3.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.90	Moderate Buy	$53.90	164.86% Upside
EBS Emergent BioSolutions	3.00	Buy	$14.33	123.96% Upside
MNKD MannKind	3.25	Buy	$10.00	142.72% Upside
NVAX Novavax	2.43	Hold	$19.00	162.07% Upside

Current Analyst Ratings Breakdown

Latest EBS, CLDX, MNKD, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/9/2025	NVAX Novavax	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$9.00 ➝ $7.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/28/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
4/10/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$12.00
4/9/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/1/2025	EBS Emergent BioSolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/21/2025	EBS Emergent BioSolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.56M	178.72	N/A	N/A	$9.08 per share	2.24
EBS Emergent BioSolutions	$930.30M	0.37	$0.72 per share	8.92	$12.51 per share	0.51
MNKD MannKind	$297.60M	4.21	N/A	N/A	($0.91) per share	-4.53
NVAX Novavax	$1.21B	0.97	N/A	N/A	($6.04) per share	-1.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$141.43M	-$2.70	N/A	N/A	N/A	-1,544.32%	-19.75%	-18.86%	N/A
EBS Emergent BioSolutions	-$760.50M	-$2.71	N/A	3.09	N/A	-18.55%	-9.91%	-3.31%	8/5/2025 (Estimated)
MNKD MannKind	-$11.94M	$0.10	58.86	17.91	N/A	8.07%	-17.74%	8.68%	8/6/2025 (Estimated)
NVAX Novavax	-$545.06M	$2.65	N/A	90.63	2.85	-32.18%	N/A	-17.05%	N/A

Latest EBS, CLDX, MNKD, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
5/7/2025	Q1 2025	EBS Emergent BioSolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
3/3/2025	Q4 2024	EBS Emergent BioSolutions	-$0.35	$0.05	+$0.40	-$0.58	$254.67 million	$194.70 million
2/27/2025	Q4 2024	CLDX Celldex Therapeutics	-$0.73	-$0.71	+$0.02	-$0.71	$1.25 million	$1.18 million
2/27/2025	Q4 2024	NVAX Novavax	-$0.75	-$0.51	+$0.24	-$0.51	$85.48 million	$88.31 million
2/26/2025	Q4 2024	MNKD MannKind	$0.03	$0.03	N/A	$0.03	$74.99 million	$76.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
EBS Emergent BioSolutions	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	24.27	24.27
EBS Emergent BioSolutions	1.30	2.88	1.47
MNKD MannKind	N/A	4.54	4.17
NVAX Novavax	N/A	0.93	0.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
EBS Emergent BioSolutions	78.40%
MNKD MannKind	49.55%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	3.80%
EBS Emergent BioSolutions	3.20%
MNKD MannKind	2.70%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.82 million	Optionable
EBS Emergent BioSolutions	2,420	54.28 million	53.53 million	Optionable
MNKD MannKind	400	303.93 million	267.51 million	Optionable
NVAX Novavax	1,990	161.97 million	158.58 million	Optionable

EBS, CLDX, MNKD, and NVAX Headlines

Recent News About These Companies

Analysts Think These Stocks Could More Than Double in Value (NVAX)

May 23 at 7:45 AM | marketbeat.com

BTIG Maintains a Buy rating on Novavax (NVAX)

May 22 at 1:02 PM | insidermonkey.com

BofA Reiterates Hold Rating on Novavax (NVAX) Stock

May 21 at 4:53 PM | msn.com

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

May 21 at 8:35 AM | seekingalpha.com

JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News

May 21 at 3:55 AM | finance.yahoo.com

Top Biotech Stocks To Research - May 19th

May 21 at 2:07 AM | americanbankingnews.com

FDA Sets New Guidelines For Approving COVID-19 Booster Shots In Healthy Individuals: Moderna, Novavax Stocks Rise

May 21 at 1:16 AM | msn.com

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

May 20, 2025 | cnbc.com

Tang Capital Management LLC Sells 400,000 Shares of Novavax, Inc. (NASDAQ:NVAX)

May 20, 2025 | marketbeat.com

JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News

May 19, 2025 | insidermonkey.com

Novavax’s Nuvaxovid Approval and Market Dynamics Justify Hold Rating Amid Unlocked Pipeline Potential

May 19, 2025 | tipranks.com

Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine

May 19, 2025 | gurufocus.com

Top Stock Movers Now: Tesla, AutoZone, Novavax, and More

May 19, 2025 | investopedia.com

Novavax Stock (NVAX) Shoots 15% Higher as Covid Vaccine Jab Gets FDA Green Light

May 19, 2025 | tipranks.com

Stock Movers Alibaba ADRs, Novavax, Reddit

May 19, 2025 | bloomberg.com

NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine

May 19, 2025 | zacks.com

Novavax Stock Soars on FDA Approval for COVID Vaccine

May 19, 2025 | schaeffersresearch.com

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.

May 19, 2025 | barrons.com

Novavax shares surge 26% after FDA grants conditional approval for Covid vaccine

May 19, 2025 | proactiveinvestors.com

Novavax jumps as FDA clears COVID-19 vaccine

May 19, 2025 | seekingalpha.com

Novavax’s COVID-19 Vaccine Gains FDA Approval

May 19, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS, CLDX, MNKD, and NVAX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$20.35 -0.02 (-0.10%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$20.34 -0.01 (-0.02%)

As of 05/23/2025 05:16 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Emergent BioSolutions NYSE:EBS

$6.40 -0.10 (-1.54%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$6.41 +0.01 (+0.16%)

As of 05/23/2025 07:58 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

MannKind NASDAQ:MNKD

$4.12 -0.10 (-2.37%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$4.15 +0.03 (+0.73%)

As of 05/23/2025 06:41 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Novavax NASDAQ:NVAX

$7.25 -0.04 (-0.55%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$7.20 -0.05 (-0.69%)

As of 05/23/2025 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time